Study Comparing Tigecycline vs. Levofloxacin in Subjects Hospitalized With Community-Acquired Pneumonia

A Phase 3, Multicenter, Randomized, Double-Blind, Comparative Study Of The Efficacy And Safety Of Intravenous Tigecycline Vs Intravenous Levofloxacin To Treat Subjects Hospitalized With Community-Acquired Pneumonia

To compare the efficacy and safety of IV tigecycline to IV levofloxacin in the treatment of subjects with CAP requiring hospitalization.

Inclusion Criteria:

• Male and female subjects ≥ 18 years of age and in Bulgaria only ≤ 70 years of age
• Subjects hospitalized with CAP with a severity that requires IV antibiotic treatment for at least 7 days
• The presence of fever (within 24 hours before randomization)

Exclusion Criteria:

• Any concomitant condition that, in the opinion of the investigator, would preclude an evaluation of a response or make it unlikely that the contemplated course of therapy could be completed (eg, life expectancy <30 days).
• Hospitalization within 14 days before the onset of symptoms.
• Residence in a long-term care facility or nursing home ≥14 days before the onset of symptoms.